IndustryCompany release

Dermata reports $74,000 in first sales after Tome skincare launch; funding lasts only into Q1 2027

🇺🇸 Dermata Therapeutics, Inc. (DRMA) · Tue 10 Nov 2026

The US dermatology company's third-quarter results show first revenue from an online cosmetic product, $5.0 million in cash and a new acne trial ahead of a planned 2027 launch.

Dermata Therapeutics reported third-quarter 2026 results on 10 November, its first quarter with revenue. Net sales were $74,000, following the online launch of its Tome Foundational Treatment cosmetic skincare product on 25 August 2026.

The company ended the period with $5.0 million in cash. It said it expects its funding to last into the first quarter of 2027, a short horizon that leaves little time before further financing would be needed.

Dermata has also begun a clinical trial of Tome Clearing Treatment, a salicylic acid product for acne. The company is targeting a launch in the first half of 2027.

The source material available for this report was limited to the company's summary of results, so details such as the trial design, enrolment, the regulatory pathway for the acne product and the cost base were not available.

What it means for your team

  • Dermata's first revenue comes from a cosmetic product sold online, not a drug approved through a medicines pathway, so the commercial start sits outside conventional drug market-access routes.
  • Teams tracking Tome Clearing Treatment should note that a clinical trial has begun and a launch is targeted for the first half of 2027; the regulatory classification was not stated in the available material.
  • The cash runway of only into Q1 2027 is a point for partners and suppliers to weigh when assessing the company's ability to deliver on its timelines.

Company's press release (SEC filing): Dermata Therapeutics, Inc. ↗

Article written by VigiEye from the official source (Dermata Therapeutics, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →